GlassScriptPhysician profile
Carmen Chau
NPI 1467009332
$2,613.42
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.60 · 2022: $1,371 · 2023: $670 · 2024: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $379.17 | 2022-2023 | Fasenra, Farxiga |
| Gilead Sciences, INC. | $365.17 | 2022-2023 | |
| Abbvie INC. | $303.64 | 2022-2024 | |
| Lilly USA, LLC | $213.21 | 2022-2023 | Jardiance, Emgality |
| Novo Nordisk INC | $204.00 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.11 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $113.70 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.98 | 2022 | |
| Alkermes, INC. | $79.04 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $68.37 | 2024 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $56.67 | 2022-2023 | Livalo, Seglentis |
| Boston Scientific Corporation | $55.82 | 2022-2023 | Watchman Access System |
| Neurocrine Biosciences, INC. | $55.79 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $53.12 | 2021-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Sanofi Pasteur INC. | $51.60 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $49.65 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $49.35 | 2024 | Rexulti |
| Pfizer INC. | $43.55 | 2022-2023 | |
| Lucid Diagnostics INC. | $41.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.88 | 2024 | Spravato |
| Currax Pharmaceuticals LLC | $27.66 | 2022-2023 | Contrave, Onzetra Xsail |
| Biotronik INC. | $22.19 | 2021 | |
| Vanda Pharmaceuticals INC. | $20.37 | 2024 | Fanapt |
| Tempus Ai, INC | $20.19 | 2024 | |
| Hologic Sales and Service, LLC | $18.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.09 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.80 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.48 | 2024 | Qelbree |
| Esperion Therapeutics, INC. | $13.64 | 2023 | Nexletol |
| Idorsia Pharmaceuticals US INC | $13.34 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.